Piper Jaffray Reiterates a 'Buy' on Myriad Genetics (MYGN), Raises Price Target and Earnings Estimates
Tweet Send to a Friend
Piper Jaffray & Co. reiterates a 'Buy' rating on Myriad Genetics (Nasdaq: MYGN), increases price target from $76 to $78.
This article: 180 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 180 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
